Therefore, it is important to consider the role of tumor microenvironment in metabolic therapies targeting GOT2 in pancreatic cancer and gain a better understanding of its potential resistance mechanisms, which will be beneficial to develop more effective metabolic therapies. This evidence concerns the gene GOT2 and neoplasm.